{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:39:00Z","timestamp":1785497940376,"version":"3.56.0"},"publisher-location":"New York, NY","reference-count":83,"publisher":"Springer New York","isbn-type":[{"value":"9781493997725","type":"print"},{"value":"9781493997732","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-1-4939-9773-2_7","type":"book-chapter","created":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T10:03:02Z","timestamp":1568023382000},"page":"155-180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Validation of Circulating Tumor DNA Assays for Detection of Metastatic Melanoma"],"prefix":"10.1007","author":[{"given":"Mahrukh M.","family":"Syeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Wiggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Broderick","family":"Corless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Spittle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Karlin-Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Polsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,10]]},"reference":[{"key":"7_CR1","first-page":"241","volume":"142","author":"P Mandel","year":"1948","unstructured":"Mandel P, Metais P (1948) Les acides nucleiques du plasma sanguin chez l'homme. CR Seances Soc Biol Fil 142:241\u2013243","journal-title":"CR Seances Soc Biol Fil"},{"key":"7_CR2","first-page":"646","volume":"37","author":"S Leon","year":"1977","unstructured":"Leon S, Shapiro B, Sklaroff D et al (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37:646\u2013650","journal-title":"Cancer Res"},{"key":"7_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10555-016-9629-x","volume":"35","author":"A Thierry","year":"2016","unstructured":"Thierry A, El Messaoudi S, Gahan P et al (2016) Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev 35:347\u2013376","journal-title":"Cancer Metastasis Rev"},{"key":"7_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cell.2015.11.050","volume":"164","author":"MW Snyder","year":"2016","unstructured":"Snyder MW, Kircher M, Hill AJ et al (2016) Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164:57\u201368","journal-title":"Cell"},{"key":"7_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006162","volume":"12","author":"HR Underhill","year":"2016","unstructured":"Underhill HR, Kitzman JO, Hellwig S et al (2016) Fragment length of circulating tumor DNA. PLoS Genet 12:e1006162","journal-title":"PLoS Genet"},{"key":"7_CR6","doi-asserted-by":"publisher","first-page":"16368","DOI":"10.1073\/pnas.0507904102","volume":"102","author":"F Diehl","year":"2005","unstructured":"Diehl F, Li M, Dressman D et al (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 102:16368\u201316373","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7_CR7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1086\/302205","volume":"64","author":"YD Lo","year":"1999","unstructured":"Lo YD, Zhang J, Leung TN et al (1999) Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 64:218\u2013224","journal-title":"Am J Hum Genet"},{"key":"7_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ et al (2014) Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med 6:224ra224","journal-title":"Sci Transl Med"},{"key":"7_CR9","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1158\/1078-0432.CCR-15-0321","volume":"22","author":"A Santiago-Walker","year":"2016","unstructured":"Santiago-Walker A, Gagnon R, Mazumdar J et\u00a0al (2016) Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. J Clin Cancer Res 22:567\u2013574","journal-title":"J Clin Cancer Res"},{"key":"7_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan2415","volume":"9","author":"J Phallen","year":"2017","unstructured":"Phallen J, Sausen M, Adleff V et al (2017) Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med 9:eaan2415","journal-title":"Sci Transl Med"},{"key":"7_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.10.029","volume":"88","author":"S Valpione","year":"2018","unstructured":"Valpione S, Gremel G, Mundra P et al (2018) Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. Eur J Cancer 88:1\u20139","journal-title":"Eur J Cancer"},{"key":"7_CR12","doi-asserted-by":"publisher","first-page":"E720","DOI":"10.1016\/S1470-2045(18)30596-5","volume":"19","author":"JJ Grob","year":"2018","unstructured":"Grob JJ, Garbe C, Ascierto P et al (2018) Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma? Lancet Oncol 19:E720\u2013E725","journal-title":"Lancet Oncol"},{"key":"7_CR13","doi-asserted-by":"crossref","unstructured":"Yushak M, Chapman P, Robert C et al (2017) Systemic therapy options for patients with unresectable melanoma. In: 2017 American Society of Clinical Oncology Annual Meeting Chicago, Illinois, pp 661\u2013672","DOI":"10.1200\/EDBK_174934"},{"key":"7_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1249559","volume":"5","author":"V Damuzzo","year":"2016","unstructured":"Damuzzo V, Solito S, Pinton L et al (2016) Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. Oncoimmunology 5:e1249559","journal-title":"Oncoimmunology"},{"key":"7_CR15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/bjc.2015.467","volume":"114","author":"S Diem","year":"2016","unstructured":"Diem S, Kasenda B, Spain L et al (2016) Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer 114:256\u2013261","journal-title":"Br J Cancer"},{"key":"7_CR16","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1002\/cncr.29586","volume":"121","author":"AM Menzies","year":"2015","unstructured":"Menzies AM, Wilmott JS, Drummond M et al (2015) Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer 121:3826\u20133835","journal-title":"Cancer"},{"key":"7_CR17","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","volume":"22","author":"B Weide","year":"2016","unstructured":"Weide B, Martens A, Hassel JC et al (2016) Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res 22:5487\u20135496","journal-title":"Clin Cancer Res"},{"key":"7_CR18","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","volume":"18","author":"AM Menzies","year":"2012","unstructured":"Menzies AM, Haydu LE, Visintin L et al (2012) Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 18:3242\u20133249","journal-title":"Clin Cancer Res"},{"key":"7_CR19","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199\u20136206","journal-title":"J Clin Oncol"},{"key":"7_CR20","doi-asserted-by":"crossref","unstructured":"Coit DG, Thompson JA, Albertini MR et al. (2019) Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","DOI":"10.6004\/jnccn.2019.0018"},{"key":"7_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/CMR.0b013e32831993cc","volume":"19","author":"F Egberts","year":"2009","unstructured":"Egberts F, Hitschler WN, Weichenthal M et al (2009) Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. Melanoma Res 19:31\u201335","journal-title":"Melanoma Res"},{"key":"7_CR22","first-page":"523","volume-title":"Cutaneous melanoma","author":"W Hwu","year":"2003","unstructured":"Hwu W, Balch C, Houghton A (2003) Diagnosis of stage IV disease. In: Balch CMHA, Sober A, Soong S (eds) Cutaneous melanoma. Quality Medical, St. Louis, pp 523\u2013546"},{"key":"7_CR23","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O'day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412\u20137420","journal-title":"Clin Cancer Res"},{"key":"7_CR24","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Cancer Genome Atlas Network. Electronic Address IMO, Cancer Genome Atlas N","year":"2015","unstructured":"Cancer Genome Atlas Network. Electronic Address IMO, Cancer Genome Atlas N (2015) Genomic classification of cutaneous melanoma. Cell 161:1681\u20131696","journal-title":"Cell"},{"key":"7_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju246","volume":"106","author":"KG Griewank","year":"2014","unstructured":"Griewank KG, Murali R, Puig-Butille JA et al (2014) TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Natl Cancer Inst 106:djv049","journal-title":"J Natl Cancer Inst"},{"key":"7_CR26","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1230062","volume":"339","author":"S Horn","year":"2013","unstructured":"Horn S, Figl A, Rachakonda PS et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339:959\u2013961","journal-title":"Science"},{"key":"7_CR27","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1126\/science.1229259","volume":"339","author":"FW Huang","year":"2013","unstructured":"Huang FW, Hodis E, Xu MJ et al (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339:957\u2013959","journal-title":"Science"},{"key":"7_CR28","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jtho.2017.04.003","volume":"12","author":"S Jenkins","year":"2017","unstructured":"Jenkins S, Yang JC, Ramalingam SS et al (2017) Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non\u2013small cell lung cancer. J Thorac Oncol 12:1061\u20131070","journal-title":"J Thorac Oncol"},{"key":"7_CR29","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nm.1789","volume":"14","author":"F Diehl","year":"2008","unstructured":"Diehl F, Schmidt K, Choti MA et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985","journal-title":"Nat Med"},{"key":"7_CR30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nmeth.2027","volume":"9","author":"M Baker","year":"2012","unstructured":"Baker M (2012) Digital PCR hits its stride. Nat Methods 9:541\u2013544","journal-title":"Nat Methods"},{"key":"7_CR31","doi-asserted-by":"publisher","first-page":"89848","DOI":"10.18632\/oncotarget.21163","volume":"8","author":"DH Hovelson","year":"2017","unstructured":"Hovelson DH, Liu C-J, Wang Y et al (2017) Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. Oncotarget 8:89848\u201389866","journal-title":"Oncotarget"},{"key":"7_CR32","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/s41467-018-04001-5","volume":"9","author":"S Manier","year":"2018","unstructured":"Manier S, Park J, Capelletti M et al (2018) Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nat Commun 9:1691","journal-title":"Nat Commun"},{"key":"7_CR33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41598-017-00520-1","volume":"7","author":"Y Shu","year":"2017","unstructured":"Shu Y, Wu X, Tong X et al (2017) Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types. Sci Rep 7:583","journal-title":"Sci Rep"},{"key":"7_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208283","volume":"13","author":"J Pel","year":"2018","unstructured":"Pel J, Leung A, Choi WW et al (2018) Rapid and highly-specific generation of targeted DNA sequencing libraries enabled by linking capture probes with universal primers. PLoS One 13:e0208283","journal-title":"PLoS One"},{"key":"7_CR35","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","volume":"7","author":"AA Chaudhuri","year":"2017","unstructured":"Chaudhuri AA, Chabon JJ, Lovejoy AF et al (2017) Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov 7:1394\u20131403","journal-title":"Cancer Discov"},{"key":"7_CR36","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jmoldx.2018.05.004","volume":"20","author":"TA Clark","year":"2018","unstructured":"Clark TA, Chung JH, Kennedy M et al (2018) Analytical validation of a hybrid capture\u2013based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA. J Mol Diagn 20:686\u2013702","journal-title":"J Mol Diagn"},{"key":"7_CR37","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jmoldx.2017.05.008","volume":"19","author":"S Bartels","year":"2017","unstructured":"Bartels S, Persing S, Hasemeier B et al (2017) Molecular analysis of circulating cell-free DNA from lung cancer patients in routine laboratory practice: a cross-platform comparison of three different molecular methods for mutation detection. J Mol Diagn 19:722\u2013732","journal-title":"J Mol Diagn"},{"key":"7_CR38","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/gim.2017.247","volume":"20","author":"K Schwarze","year":"2018","unstructured":"Schwarze K, Buchanan J, Taylor JC et al (2018) Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med 20:1122\u20131130","journal-title":"Genet Med"},{"key":"7_CR39","unstructured":"Premarket Approval (PMA) cobas EGFR Mutation Test v2 (2016) US Food & Drug Administration. https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm504540.htm"},{"key":"7_CR40","first-page":"155","volume":"15","author":"SA Bustin","year":"2004","unstructured":"Bustin SA, Nolan T (2004) Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. J Biomol Tech 15:155\u2013166","journal-title":"J Biomol Tech"},{"issue":"12","key":"7_CR41","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1158\/1078-0432.CCR-12-0871","volume":"18","author":"AL Richardson","year":"2012","unstructured":"Richardson AL, Iglehart JD (2012) BEAMing up personalized medicine: mutation detection in blood. Clin Cancer Res 18(12):3209\u20133211","journal-title":"Clin Cancer Res"},{"key":"7_CR42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-014-0042-0","volume":"2","author":"EJ Lipson","year":"2014","unstructured":"Lipson EJ, Velculescu VE, Pritchard TS et al (2014) Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer 2:42","journal-title":"J Immunother Cancer"},{"key":"7_CR43","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/1878-0261.12373","volume":"12","author":"SP Rowe","year":"2018","unstructured":"Rowe SP, Luber B, Makell M et al (2018) From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting. Mol Oncol 12:1661\u20131672","journal-title":"Mol Oncol"},{"key":"7_CR44","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1177\/2472630317705680","volume":"22","author":"AS Basu","year":"2017","unstructured":"Basu AS (2017) Digital assays part I: partitioning statistics and digital PCR. SLAS Technol 22:369\u2013386","journal-title":"SLAS Technol"},{"key":"7_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-1-4939-7778-9_2","volume-title":"Digital PCR","author":"L Pinheiro","year":"2018","unstructured":"Pinheiro L, Emslie KR (2018) Basic concepts and validation of digital PCR measurements. In: Digital PCR. Springer, New York, pp 11\u201324"},{"key":"7_CR46","doi-asserted-by":"publisher","first-page":"8604","DOI":"10.1021\/ac202028g","volume":"83","author":"BJ Hindson","year":"2011","unstructured":"Hindson BJ, Ness KD, Masquelier DA et al (2011) High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 83:8604\u20138610","journal-title":"Anal Chem"},{"key":"7_CR47","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bdq.2014.08.001","volume":"1","author":"CA Milbury","year":"2014","unstructured":"Milbury CA, Zhong Q, Lin J et\u00a0al (2014) Determining lower limits of detection of digital PCR assays for cancer-related gene mutations. Biomol Detect Quantif 1:8\u201322","journal-title":"Biomol Detect Quantif"},{"key":"7_CR48","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1373\/clinchem.2014.230235","volume":"61","author":"MF Sanmamed","year":"2015","unstructured":"Sanmamed MF, Fernandez-Landazuri S, Rodriguez C et al (2015) Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem 61:297\u2013304","journal-title":"Clin Chem"},{"key":"7_CR49","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jmoldx.2018.09.003","volume":"21","author":"BC Corless","year":"2019","unstructured":"Corless BC, Chang GA, Cooper S et al (2019) Development of novel mutation-specific droplet digital PCR assays detecting TERT promoter mutations in tumor and plasma samples. J Mol Diagn 21:274\u2013285","journal-title":"J Mol Diagn"},{"key":"7_CR50","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-13-2482","volume":"20","author":"GR Oxnard","year":"2014","unstructured":"Oxnard GR, Paweletz CP, Kuang Y et al (2014) Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 20:1698\u20131705","journal-title":"Clin Cancer Res"},{"key":"7_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153901","volume":"11","author":"SD Findlay","year":"2016","unstructured":"Findlay SD, Vincent KM, Berman JR et al (2016) A digital PCR-based method for efficient and highly specific screening of genome edited cells. PLoS One 11:e0153901","journal-title":"PLoS One"},{"key":"7_CR52","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jmoldx.2015.09.003","volume":"18","author":"R Bidshahri","year":"2016","unstructured":"Bidshahri R, Attali D, Fakhfakh K et al (2016) Quantitative detection and resolution of BRAF V600 status in colorectal cancer using droplet digital PCR and a novel wild-type negative assay. J Mol Diagn 18:190\u2013204","journal-title":"J Mol Diagn"},{"key":"7_CR53","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1373\/clinchem.2017.272518","volume":"64","author":"C Decraene","year":"2018","unstructured":"Decraene C, Silveira AB, Bidard F-C et al (2018) Multiple hotspot mutations scanning by single droplet digital PCR. Clin Chem 64:317\u2013328","journal-title":"Clin Chem"},{"key":"7_CR54","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.stem.2018.01.011","volume":"22","author":"RL Bowman","year":"2018","unstructured":"Bowman RL, Busque L, Levine RL (2018) Clonal hematopoiesis and evolution to hematopoietic malignancies. Cell Stem Cell 22:157\u2013170","journal-title":"Cell Stem Cell"},{"key":"7_CR55","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1161\/CIRCRESAHA.117.312115","volume":"122","author":"JJ Fuster","year":"2018","unstructured":"Fuster JJ, Walsh K (2018) Somatic mutations and clonal hematopoiesis: unexpected potential new drivers of age-related cardiovascular disease. Circ Res 122:523\u2013532","journal-title":"Circ Res"},{"key":"7_CR56","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1158\/1078-0432.CCR-18-0143","volume":"24","author":"Y Hu","year":"2018","unstructured":"Hu Y, Ulrich B, Supplee J et\u00a0al (2018) False positive plasma genotyping due to clonal hematopoiesis. Clin Cancer Res 24:4437\u20134443","journal-title":"Clin Cancer Res"},{"key":"7_CR57","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40425-016-0178-1","volume":"4","author":"GV Masucci","year":"2016","unstructured":"Masucci GV, Cesano A, Hawtin R et al (2016) Validation of biomarkers to predict response to immunotherapy in cancer: Volume I\u2014pre-analytical and analytical validation. J Immunother Cancer 4:76","journal-title":"J Immunother Cancer"},{"key":"7_CR58","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s11095-005-9045-3","volume":"23","author":"JW Lee","year":"2005","unstructured":"Lee JW, Devanarayan V, Barrett YC et al (2005) Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 23:312\u2013328","journal-title":"Pharm Res"},{"key":"7_CR59","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40425-016-0179-0","volume":"4","author":"KK Dobbin","year":"2016","unstructured":"Dobbin KK, Cesano A, Alvarez J et\u00a0al (2016) Validation of biomarkers to predict response to immunotherapy in cancer: Volume II\u2014clinical validation and regulatory considerations. J Immunother Cancer 4:77","journal-title":"J Immunother Cancer"},{"key":"7_CR60","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1007\/s00216-014-7835-3","volume":"406","author":"AS Devonshire","year":"2014","unstructured":"Devonshire AS, Whale AS, Gutteridge A et al (2014) Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem 406:6499\u20136512","journal-title":"Anal Bioanal Chem"},{"key":"7_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150197","volume":"11","author":"JL Sherwood","year":"2016","unstructured":"Sherwood JL, Corcoran C, Brown H et al (2016) Optimised pre-analytical methods improve KRAS mutation detection in circulating tumour DNA (ctDNA) from patients with non-small cell lung cancer (NSCLC). PLoS One 11:e0150197","journal-title":"PLoS One"},{"key":"7_CR62","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1046\/j.1537-2995.2001.41020276.x","volume":"41","author":"TH Lee","year":"2001","unstructured":"Lee TH, Montalvo L, Chrebtow V et al (2001) Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion 41:276\u2013282","journal-title":"Transfusion"},{"key":"7_CR63","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-16-1691","volume":"23","author":"S Parpart-Li","year":"2017","unstructured":"Parpart-Li S, Bartlett B, Popoli M et al (2017) The effect of preservative and temperature on the analysis of circulating tumor DNA. Clin Cancer Res 23:2471\u20132477","journal-title":"Clin Cancer Res"},{"key":"7_CR64","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.clinbiochem.2015.02.014","volume":"48","author":"GB Barra","year":"2015","unstructured":"Barra GB, Santa Rita TH, De Almeida Vasques J et\u00a0al (2015) EDTA-mediated inhibition of DNases protects circulating cell-free DNA from ex vivo degradation in blood samples. Clin Biochem 48:976\u2013981","journal-title":"Clin Biochem"},{"key":"7_CR65","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/cam4.1184","volume":"6","author":"JH Van Ginkel","year":"2017","unstructured":"Van Ginkel JH, Van Den Broek DA, Van Kuik J et\u00a0al (2017) Preanalytical blood sample workup for cell-free DNA analysis using Droplet Digital PCR for future molecular cancer diagnostics. Cancer Med 6:2297\u20132307","journal-title":"Cancer Med"},{"key":"7_CR66","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1373\/clinchem.2003.026013","volume":"50","author":"NYL Lam","year":"2004","unstructured":"Lam NYL, Rainer TH, Chiu RWK et al (2004) EDTA is a better anticoagulant than heparin or citrate for delayed blood processing for plasma DNA analysis. Clin Chem 50:256\u2013257","journal-title":"Clin Chem"},{"key":"7_CR67","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000335020","volume":"31","author":"M Hidestrand","year":"2012","unstructured":"Hidestrand M, Stokowski R, Song K et al (2012) Influence of temperature during transportation on cell-free DNA analysis. Fetal Diagn Ther 31:122\u2013128","journal-title":"Fetal Diagn Ther"},{"key":"7_CR68","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.pathol.2017.08.010","volume":"49","author":"CA Hyland","year":"2017","unstructured":"Hyland CA, Millard GM, O'brien H et al (2017) Non-invasive fetal RHD genotyping for RhD negative women stratified into RHD gene deletion or variant groups: comparative accuracy using two blood collection tube types. Pathology 49:757\u2013764","journal-title":"Pathology"},{"key":"7_CR69","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40291-017-0284-x","volume":"21","author":"K Warton","year":"2017","unstructured":"Warton K, Yuwono NL, Cowley MJ et al (2017) Evaluation of Streck BCT and PAXgene stabilised blood collection tubes for cell-free circulating DNA studies in plasma. Mol Diagn Ther 21:563\u2013570","journal-title":"Mol Diagn Ther"},{"key":"7_CR70","doi-asserted-by":"publisher","first-page":"7375","DOI":"10.1038\/s41598-018-25810-0","volume":"8","author":"H Markus","year":"2018","unstructured":"Markus H, Contente-Cuomo T, Farooq M et al (2018) Evaluation of pre-analytical factors affecting plasma DNA analysis. Sci Rep 8:7375","journal-title":"Sci Rep"},{"key":"7_CR71","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/clinchem\/47.9.1607","volume":"47","author":"RW Chiu","year":"2001","unstructured":"Chiu RW, Poon LL, Lau TK et al (2001) Effects of blood-processing protocols on fetal and total DNA quantification in maternal plasma. Clin Chem 47:1607\u20131613","journal-title":"Clin Chem"},{"key":"7_CR72","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jmoldx.2016.09.009","volume":"19","author":"L Sorber","year":"2017","unstructured":"Sorber L, Zwaenepoel K, Deschoolmeester V et al (2017) A comparison of cell-free DNA isolation kits: isolation and quantification of cell-free DNA in plasma. J Mol Diagn 19:162\u2013168","journal-title":"J Mol Diagn"},{"key":"7_CR01","doi-asserted-by":"crossref","unstructured":"Syeda MM, Karlin-Neumann G, Osman I, Polsky D (2019) Analysis of nucleosomal DNA as an extraction control for plasma-based circulating tumor DNA assays [abstract]. In: Proceedings of the 110th Annual Meeting of the American Association for Cancer Research; 2019 March 29\u2013April 3; Atlanta, GA. Philadelphia (PA): AACR; 2019. Abstract #2239","DOI":"10.1158\/1538-7445.AM2019-2239"},{"key":"7_CR73","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMra1706174","volume":"379","author":"RB Corcoran","year":"2018","unstructured":"Corcoran RB, Chabner BA (2018) Application of Cell-free DNA analysis to cancer treatment. N Engl J Med 379:1754\u20131765","journal-title":"N Engl J Med"},{"key":"7_CR74","unstructured":"Bioanalytical Method Validation Guidance for Industry (2018) U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). https:\/\/www.fda.gov\/media\/70858\/download"},{"key":"7_CR75","unstructured":"Cobas EGFR Mutation Test v2 FDA Summary of Safety and Effectiveness Data (2016) US Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf15\/P150047B.pdf"},{"key":"7_CR76","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1373\/clinchem.2013.211045","volume":"59","author":"TC Dingle","year":"2013","unstructured":"Dingle TC, Sedlak RH, Cook L et al (2013) Tolerance of droplet-digital PCR vs. real-time quantitative PCR to inhibitory substances. Clin Chem 59:1670\u20131672","journal-title":"Clin Chem"},{"key":"7_CR77","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","volume":"15","author":"GA Mcarthur","year":"2014","unstructured":"Mcarthur GA, Chapman PB, Robert C et al (2014) Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15:323\u2013332","journal-title":"Lancet Oncol"},{"key":"7_CR78","first-page":"S49","volume":"29","author":"DA Armbruster","year":"2008","unstructured":"Armbruster DA, Pry T (2008) Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev 29:S49\u2013S52","journal-title":"Clin Biochem Rev"},{"key":"7_CR79","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.canlet.2017.06.030","volume":"404","author":"L Calapre","year":"2017","unstructured":"Calapre L, Warburton L, Millward M et al (2017) Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Lett 404:62\u201369","journal-title":"Cancer Lett"},{"key":"7_CR80","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","volume":"28","author":"J Lee","year":"2017","unstructured":"Lee J, Long G, Boyd S et al (2017) Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol 28:1130\u20131136","journal-title":"Ann Oncol"},{"key":"7_CR81","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/annonc\/mdx717","volume":"29","author":"RJ Lee","year":"2017","unstructured":"Lee RJ, Gremel G, Marshall A et al (2017) Circulating tumor DNA predicts survival in patients with resected high-risk stage II\/III melanoma. Ann Oncol 29:490\u2013496","journal-title":"Ann Oncol"},{"key":"7_CR02","doi-asserted-by":"crossref","unstructured":"Syeda MM, Corless B, Wilson M, Lee Y, Tchack J, Wechter T, Moran U, Karlin-Neumann G, Pavlick AC, Osman I, Shao Y, Polsky D (2018) Analysis of TERTmutant circulating tumor DNA as a potential biomarker of disease activity in patients with unresectable stage III\/IV melanoma receiving immuno-oncology therapies [abstract]. In: Proceedings of the 109th Annual Meeting of the American Association for Cancer Research; 2018 Apr 14\u201318; Chicago, Illinois. Philadelphia (PA): AACR; 2018. Abstract #5534","DOI":"10.1158\/1538-7445.AM2018-5534"}],"container-title":["Methods in Molecular Biology","Biomarkers for Immunotherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-9773-2_7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T01:13:58Z","timestamp":1649812438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-4939-9773-2_7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,10]]},"ISBN":["9781493997725","9781493997732"],"references-count":83,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-9773-2_7","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,10]]},"assertion":[{"value":"10 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}